ClinicalTrials.gg
Active, not recruitingNCT06111586FABULINUSUpdated Nov 2, 2026

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

A Phase 2 interventional study of Frexalimab and Placebo in Type 1 Diabetes Mellitus, sponsored by Sanofi. Active, not recruiting at 79 sites in 16 countries. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Updated Nov 2, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
197
Allocation
Randomized
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Diabetes Mellitus, Type 1 by Sanofi — 6 open to participants now, 10 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Sanofi.

Enrollment
20th of 60
197 · median 86
Started
2023
with 1 other
Phase 2
5 of 67
none open now
Registered
58th of 67
by date

Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 20th largest by enrollment of the 60 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 2, and was the 58th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

6 of the 67 studies in Diabetes Mellitus, Type 1 by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Diabetes Mellitus, Type 1 by Sanofi, or all of them as a file.
02

Study summary

This is a randomized, parallel group, double-blind Phase 2 study with a blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment.

Study details include:

Screening period: at least 3 weeks and up to 5 weeks. Enrollment date of the participant must take into consideration this constraint)

Double-blind treatment period 104 weeks:

Main treatment period: 52 weeks Blinded extension: 52 weeks Optional OLE period: 104 weeks Safety follow-up: 26 weeks The treatment duration will be up to 104 weeks , the total study duration will be up to 135 weeks for Part A and Part B.

If participants enter the OLE period, the treatment duration will be up to approximately 208 weeks , and the total study duration will be 240 weeks approximately .

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who meet the criteria of T1D according to American Diabetes Association
  • Initiated exogenous insulin replacement therapy not longer than 90 days prior to screening visit at which random C-peptide will be assessed (V1).
  • Receiving at least one of the following T1D standard of care (SOC), insulin hormone replacement therapy

    • one or multiple daily injections (MDI) of basal insulin, prandial insulin and/or premixed insulin, or
    • continuous subcutaneous insulin infusion (CSII)
  • Participants must be positive for at least 1 of the following T1D autoantibodies confirmed by medical history and/or obtained at study screening:

    • Glutamic acid decarboxylase (GAD-65)
    • Insulinoma Antigen-2 (IA-2)
    • Zinc-transporter 8 (ZnT8) or
    • Insulin (if obtained not later than 10 days after exogenous insulin therapy initiation)
  • Have random C-peptide levels ≥ 0.2 nmol/L determined at screening visit.
  • Be vaccinated according to the local vaccination schedule. Any vaccinations should take place at least 28 days prior to randomization for non- and at least 3 months prior to randomization for live vaccines.
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • Participants body weight at screening must be at least 20kg.

Exclusion criteria

Exclusion Criteria:

  • Serious systemic viral, bacterial or fungal infection (eg, pneumonia, pyelonephritis), infection requiring hospitalization or IV antibiotics or significant chronic viral (including history of recurrent or active herpes zoster, acute or active cytomegalovirus (CMV), Epstein-Barr Virus (EBV) as determined at screening), bacterial, or fungal infection (eg, osteomyelitis) 30 days before and during screening.
  • Participants with a history of invasive opportunistic infections, such as, but not limited to histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jirovecii, and aspergillosis, regardless of resolution.
  • Evidence of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (posterior anterior and lateral), and/or TB testing. Blood testing (eg, QuantiFERON® TB Gold test) is strongly preferred; if not available, any local approved TB test is allowed.
  • Evidence of any , severe or unstable, acute or chronically progressive, uncontrolled infection, medical or surgical condition (eg, but not limited to, cerebral, cardiac, pulmonary, renal, hepatic, gastrointestinal, neurologic, acquired or inherited bone/skeletal disorders including repeated bone fractures for unknown reason, juvenile osteoporosis, osteogenesis imperfecta, osteochondropathies, or any known immune deficiency), or any condition that may affect participant safety in the judgment of the Investigator (including vaccinations which are not updated based on local regulation).
  • History or current hypogammaglobulinemia.
  • History of a systemic reaction or significant allergies, other than localized injection site reaction, to any humanized mAb. Clinically significant multiple or severe drug allergies, intolerance to topical , or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
  • Has other diseases (eg, rheumatoid arthritis [RA], polyarticular juvenile idiopathic arthritis [pJIA], psoriatic arthritis [PsA], ankylosing spondylitis [AS], MS, SLE), that require treatment with biologic drugs (mono or polyclonal antibodies) or systemic corticosteroid therapy (at discretion of investigator).
  • History, clinical evidence, suspicion or significant risk for thromboembolic events, as well as myocardial infarction, stroke, antiphospholipid syndrome, other prothrombotic disorders and/or participants requiring antithrombotic treatment.
  • Diabetes of forms other than autoimmune T1D that include but is not limited to genetic forms of diabetes, maturity-onset diabetes of the young (MODY), latent autoimmune diabetes of the adult (LADA), secondary to medications or surgery, type 2 diabetes by judgement of the investigator.
  • History of of any organ system, treated or untreated, within 5 years of screening, regardless of whether there is evidence of local recurrence or .
  • Systemic corticosteroids (duration > 7 days), adrenocorticotropic hormone 1 month prior to screening.
  • Any IV, IM or SC administered biologic treatments, \< 3 months or \< than 5 half-lives (whichever is longer), prior to randomization.
  • Any live (attenuated or viral-vector) vaccine (including but not limited to varicella zoster, oral polio, nasal influenza, rabies) within 3 months prior to randomization.
  • Any non-live (inactivated, mRNA, recombinant, conjugate, toxoid) vaccine administered less than 28 days prior to randomization.
  • Other medications not compatible or interfering with IMP at discretion of investigator.
  • Any therapy within 12 weeks prior to randomization.
  • Course of Thymoglobulin®, teplizumab or other immunomodulatory treatments at any time.
  • Any drugs that may be used for treatment of T1D and type 2 diabetes other than insulin including but not limited to metformin, glucagon-like peptide 1 (GLP-1) agonists and sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor and verapamil within 2 weeks prior to screening.
  • Abnormal laboratory test(s) at screening.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
197 participants (actual)

Study arms

  • Experimental
    Frexalimab Dose 1

    Drug: Frexalimab · Drug: Insulin

  • Experimental
    Frexalimab Dose 2

    Drug: Frexalimab · Drug: Insulin

  • Experimental
    Frexalimab Dose 3

    Drug: Frexalimab · Drug: Insulin

  • Placebo comparator
    Placebo

    Matching Placebo

    Drug: Placebo · Drug: Insulin

Interventions

  • IV Infusion at Day 1 SC Injection from W2 to W102

  • DrugPlacebo

    IV Infusion at Day 1 SC Injection from W2 to W102

  • SC injection, dose and frequency will be established and/or adjusted by investigator

06

What researchers measure

Primary outcomes

  1. Change in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from AUC from baseline to W52 for Part B (12-21 y.o.)

    mixed meal tolerance test (MMTT) stimulated C-peptide concentration is to be calculated from AUC

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Time in range (70-180 mg/dL), assessed by CGM at W52 and W104(part B)

    Time frame: At Week 52 and Week 104

  2. Proportion of participants who remain C-peptide positive (mean 2h MMTT stimulated C-peptide concentration ≥0.2 nmol/L) at W52 and W104(part B)

    mixed meal tolerance test (MMTT) stimulated C-peptide concentration is to be calculated from AUC

    Time frame: At Week 52 and Week 104

  3. Proportion of participants with reduction from baseline to W52 and W104 of less than 10% in mean 2h MMTT stimulated C-peptide concentration(part B)

    mixed meal tolerance test (MMTT) stimulated C-peptide concentration is to be calculated from AUC

    Time frame: From baseline to Week 52 and Week 104

  4. Proportion of participants with partial remission at W52 and W104 (defined as IDAA1c score ≤9.0, where it is calculated as HbA1c [%] + 4x insulin dose [IU/kg/day])(part B)

    Time frame: At Week 52 and Week 104

  5. Change from baseline to W52 and W104 in insulin dose [IU/kg/day](part B)

    Time frame: From baseline to Week 52 and Week 104

  6. HbA1c level at Week 52 and Week 104(part B)

    Time frame: at Week 52 and Week 104

  7. Proportion of participants with HbA1c ≤6.5% and requiring no injections of exogenous insulin at W52 and W104(part B)

    Time frame: At Week 52 and Week 104

  8. Proportion of participants with HbA1c ≤6.5% and requiring ≤0.25 IU of insulin at W52 and W104(part B)

    Time frame: At Week 52 and Week 104

  9. Proportion of participants with HbA1c <7% at W52 and W104(part B)

    Time frame: At Week 52 and Week 104

  10. Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs) and TEAEs leading to treatment discontinuation

    Time frame: Until Week 130

  11. Number of participants with at least one hypoglycemic event

    Time frame: Until Week 130

  12. Number of participants with at least one hyperglycemic episode

    Time frame: Until Week 130

  13. Number of participants with at least one diabetic ketoacidosis (DKA) event

    Time frame: Until Week 130

  14. Number of participants with clinically significant changes in vital signs, electrocardiogram (ECG), and/or laboratory evaluation

    Time frame: Until Week 130

  15. Height and growth rate over time (for participants <18 y.o. at screening)

    Time frame: Until Week 130

  16. Frexalimab plasma concentrations over time

    Time frame: Until Week 104

  17. Incidence of anti-drug antibodies (ADAs) over time

    Time frame: Until Week 130

  18. Change from baseline to W52 and W104 in PedsQL Diabetes Symptoms domain score (all participants≥8 y.o.) (part B)

    Time frame: From baseline to Week 52 and Week 104

  19. Change from baseline to W52 and W104 in Pediatric Quality of Life (PedsQL) Diabetes Management domain score (all participants≥8 y.o.) (part B)

    Time frame: From baseline to Week 52 and Week 104

  20. Change from baseline to W52 and W104 in Problem Areas In Diabetes (PAID) total score (all participants)(part B)

    Time frame: From baseline to Week 52 and Week 104

  21. Change from baseline to W52 and W104 in Diabetes Treatment Satisfaction Questionnaires (DTSQs) total and item scores (all participants)(part B)

    Time frame: From baseline to Week 52 and Week 104

  22. Change from baseline to W52 and W104 in PAID immediate and theoretical domain scores (caregivers of all participants 12-17 y.o.)(part B)

    Time frame: From baseline to Week 52 and Week 104

  23. Change from baseline to W52 and W104 in DTSQs Total and item scores (caregivers of all participants 12-17 y.o.)(part B)

    Time frame: From baseline to Week 52 and Week 104

  24. Time in tight range (TITR, 70 - 140 mg/dL), assessed by CGM at W52 and W104(part B)

    Time frame: Time in tight range (TITR, 70 - 140 mg/dL), assessed by CGM at W52 and W104

  25. Change from baseline to W104 in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from AUC(part B)

    Time frame: From baseline to Week 104

  26. Change from baseline to W52 and W104 in IDAA1c score(part B)

    Time frame: From baseline to Week 52

  27. HbA1c level change from baseline to Week 52 and Week 104(part B)

    Time frame: From baseline to Week 52 and Week 104

07

Study locations

79 sites
  • University of California San Francisco - Mission Bay- Site Number : 8400012
    San Francisco, California 94158, United States
  • University of Colorado - Anschutz Medical Campus- Site Number : 8400003
    Aurora, Colorado 80045, United States
  • University of Florida College of Medicine- Site Number : 8400010
    Gainesville, Florida 32610, United States
  • University of Miami Hospital- Site Number : 8400013
    Miami, Florida 33136, United States
  • AdventHealth Orlando- Site Number : 8400002
    Orlando, Florida 32803, United States
  • Rocky Mountain Diabetes and Osteoporosis Center- Site Number : 8400009
    Idaho Falls, Idaho 83404, United States
  • NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8400007
    Skokie, Illinois 60077, United States
  • Joslin Diabetes Center - Boston- Site Number : 8400015
    Boston, Massachusetts 02215, United States
  • University at Buffalo - Downtown Campus- Site Number : 8400004
    Buffalo, New York 14203, United States
  • University of North Carolina at Chapel Hill- Site Number : 8400001
    Chapel Hill, North Carolina 27514, United States
  • Cincinnati Children's Hospital Medical Center- Site Number : 8400019
    Cincinnati, Ohio 45229, United States
  • The Children's Hospital of Philadelphia Site Number : 8400005
    Philadelphia, Pennsylvania 19104, United States
  • University of Texas - Southwestern Medical Center- Site Number : 8400011
    Dallas, Texas 75390, United States
  • Benaroya Research Institute at Virginia Mason- Site Number : 8400016
    Seattle, Washington 98101, United States
  • Investigational Site Number : 0400002
    Graz, 8036, Austria
  • Investigational Site Number : 0400004
    Linz, 4020, Austria
  • Investigational Site Number : 0400001
    Vienna, 1090, Austria
  • Investigational Site Number : 0560002
    Brussels, 1090, Belgium
  • Investigational Site Number : 0560001
    Leuven, 3000, Belgium
  • Investigational Site Number : 1240001
    Vancouver, British Columbia V5Y 3W2, Canada
  • Investigational Site Number : 1240007
    London, Ontario N6a 4l6, Canada
  • Investigational Site Number : 1240005
    Montreal, Quebec H3T 1C5, Canada
  • Investigational Site Number : 1240004
    Montreal, Quebec H4a 3j1, Canada
  • Investigational Site Number : 1240003
    Montreal, Quebec H4A 3T2, Canada
  • Investigational Site Number : 2030003
    Ostrava, 708 52, Czechia
  • Investigational Site Number : 2030002
    Prague, 100 34, Czechia
  • Investigational Site Number : 2030001
    Prague, 150 06, Czechia
  • Investigational Site Number : 2080005
    Herlev, 2730, Denmark
  • Investigational Site Number : 2460001
    Helsinki, 00029, Finland
  • Investigational Site Number : 2460004
    Oulu, 90220, Finland
  • Investigational Site Number : 2460003
    Tampere, 33520, Finland
  • Investigational Site Number : 2460002
    Turku, 20521, Finland
  • Investigational Site Number : 2500004
    Corbeil-Essonnes, 91106, France
  • Investigational Site Number : 2500005
    Mont-de-Marsan, 40024, France
  • Investigational Site Number : 2500006
    Paris, 75679, France
  • Investigational Site Number : 2500007
    Pontoise, 95300, France
  • Investigational Site Number : 2500003
    Saint-Herblain, 44800, France
  • Investigational Site Number : 2760003
    Dresden, 01307, Germany
  • Investigational Site Number : 2760001
    Hanover, 30173, Germany
  • Investigational Site Number : 2760002
    Oldenburg in Holstein, 23758, Germany
  • Investigational Site Number : 2760004
    Ulm, 89081, Germany
  • Investigational Site Number : 3480001
    Balatonfüred, 8230, Hungary
  • Investigational Site Number : 3480004
    Budapest, 1089, Hungary
  • Investigational Site Number : 3480002
    Nyíregyháza, 4400, Hungary
  • Investigational Site Number : 3480003
    Nyíregyháza, 4400, Hungary
  • Investigational Site Number : 3480006
    Székesfehérvár, 8000, Hungary
  • AOU delle Marche - Ospedale G. Salesi-Site Number : 3800008
    Torette, Ancona 60020, Italy
  • Azienda Ospedaliera Universitaria Meyer IRCCS-Site Number : 3800003
    Florence, Firenze 50139, Italy
  • IRCCS Ospedale San Raffaele-Site Number : 3800006
    Milan, Milano 20132, Italy
  • Azienda Ospedaliera Universitaria 'Federico II'-Site Number : 3800009
    Naples, Napoli 80131, Italy
  • Ospedale Pediatrico Bambin Gesu IRCCS-Site Number : 3800007
    Rome, Roma 00165, Italy
  • Azienda Ospedaliero-Universitaria Maggiore Della Carità-Site Number : 3800001
    Novara, 28100, Italy
  • Azienda Socio Sanitaria Territoriale Dei Sette Laghi - Ospedale Filippo del Ponte-Site Number : 3800002
    Varese, 21100, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona - Centro regionale di Diabetologia Pediatrica-Site Number : 3800004
    Verona, 37126, Italy
  • Investigational Site Number : 6160005
    Lodz, Lódzkie 92-213, Poland
  • Investigational Site Number : 6160006
    Warsaw, Masovian Voivodeship 02-097, Poland
  • Investigational Site Number : 6160004
    Warsaw, Masovian Voivodeship 02-117, Poland
  • Investigational Site Number : 6160007
    Warsaw, Masovian Voivodeship 04-746, Poland
  • Investigational Site Number : 6160008
    Bialystok, Podlaskie Voivodeship 15-274, Poland
  • Investigational Site Number : 6160002
    Katowice, Silesian Voivodeship 40-752, Poland
  • Investigational Site Number : 6160009
    Szczecin, West Pomeranian Voivodeship 71-252, Poland
  • Investigational Site Number : 7050001
    Ljubljana, 1000, Slovenia
  • Investigational Site Number : 7240001
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Investigational Site Number : 7240002
    Esplugues de Llobregat, Barcelona [Barcelona] 08950, Spain
  • Investigational Site Number : 7240005
    Oviedo, Principality of Asturias 33011, Spain
  • Investigational Site Number : 7240003
    Seville, Sevilla 41009, Spain
  • Investigational Site Number : 7240004
    Málaga, 29010, Spain
  • Investigational Site Number : 7240006
    Valencia, 46010, Spain
  • Investigational Site Number : 7240007
    Vitoria-Gasteiz, Álava 01009, Spain
  • Investigational Site Number : 7520002
    Solna, 171 64, Sweden
  • Investigational Site Number : 7520001
    Stockholm, 113 65, Sweden
  • Investigational Site Number : 7520003
    Stockholm, 118 83, Sweden
  • Investigational Site Number : 8260001
    Cambridge, Cambridgeshire CB2 2QQ, United Kingdom
  • Investigational Site Number : 8260009
    Dundee, Dundee City DD1 9SY, United Kingdom
  • Investigational Site Number : 8260003
    Birmingham, England B15 2TH, United Kingdom
  • Investigational Site Number : 8260007
    Birmingham, England B4 6NH, United Kingdom
  • Investigational Site Number : 8260010
    Glasgow, Glasgow City G51 4TF, United Kingdom
  • Investigational Site Number : 8260004
    Leicester, Leicestershire LE5 4PW, United Kingdom
  • Investigational Site Number : 8260006
    Harrow, London, City of HA1 3UJ, United Kingdom
08

References and documents

Publications

  • Cherkas A, Rotthaeuser B, Porksen N, Labard P, Nguyen-Pascal ML, Coudert M, Berthou B, Baccara-Dinet M, Boka G, Peakman M, Reschke F, Haller MJ. A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent-Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design. Diabetes Obes Metab. 2026 Aug;28(8):6584-6594. doi: 10.1111/dom.70785. Epub 2026 May 27. PubMed 42203212 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Apr 2027, 40 months after the start.

Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 40 months is above that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2023
First posted
Nov 1, 2023
StartActual
Dec 11, 2023
Primary completionEst.
Apr 28, 2027
CompletionEst.
Oct 29, 2030
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Minimum age 6 Years→12 Years
Nov 2, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedChange in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from AUC from baseline to W26 for Part C (6-11 y.o.)Time frame: Baseline to Week 26
Nov 2, 2026
Secondary outcomes
19 removed
What changed in the outcomes
  • RemovedTime in range (70-180 mg/dL), assessed by study CGM at W26 and W52(part C)Time frame: At week 26 and week 52
  • RemovedTime in tight range (TITR, 70 - 140 mg/dL), assessed by study CGM at W26 and W52(part C)Time frame: At Week 26 and Week 52
  • RemovedChange from baseline to W52 in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from AUC(Part C)Time frame: From baseline to week 52
  • RemovedProportion of participants who remain C-peptide positive (mean 2h MMTT stimulated C-peptide concentration ≥0.2 nmol/L) at W26 and W52(part C)Time frame: At Week 26 and Week 52
  • RemovedProportion of participants with reduction from baseline to W26 and W52 of less than 10% in mean 2h MMTT stimulated C-peptide concentration(Part C)Time frame: From baseline to week 26 and week 52
  • RemovedProportion of participants with partial remission at W26 and W52 (defined as IDAA1c score ≤9.0, where it is calculated as HbA1c [%] + 4x insulin dose [IU/kg/day]) (part C)Time frame: At week 26 and week 52
  • RemovedChange from baseline to W26 and W52 in IDAA1c score(part C)Time frame: From baseline to Week 26 and Week 52
  • RemovedChange from baseline to W26 and W52 in insulin dose [IU/kg/day] (part C)Time frame: From baseline to Week 26 and Week 52
  • RemovedProportion of participants with HbA1c ≤6.5% and requiring no injections of exogenous insulin at W26 and W52(part C)Time frame: At week 26 and week 52
  • RemovedProportion of participants with HbA1c ≤6.5% and requiring ≤0.25 IU of insulin at W26 and W52(part C)Time frame: At week 26 and week 52
  • RemovedProportion of participants with HbA1c <7% at W26 and W52(part C)Time frame: At week 26 and week 52
  • RemovedChange from baseline to W26 and W52 in PedsQL Diabetes Symptoms domain score (all participants≥8 y.o.) (part C)Time frame: From baseline to Week 26 and Week 52
  • RemovedChange from baseline to W26 and W52 in [BB7.1][LS7.2]PedsQL Diabetes Management domain score (all participants≥8 y.o.) (part C)Time frame: From baseline to Week 26 and Week 52
  • RemovedChange from baseline to W26 and W52 in Problem Areas In Diabetes (PAID) total score (all participants)(part C)Time frame: From baseline to Week 26 and Week 52
  • RemovedChange in PedsQL Diabetes Symptoms and Management domains scores (caregivers of participants 6 -7 y.o.) from baseline to W26 and W52 (Part C)Time frame: From baseline to Week 26 and Week 52
  • RemovedChange from baseline to W26 and W52 in PAID immediate and theoretical domain scores (caregivers of all participants 6-17 y.o.)(part C)Time frame: From baseline to Week 26 and Week 52
  • RemovedChange from baseline to W26 and W52 [BB8.1]in DTSQs Total and item scores (caregivers of all participants 6-17 y.o.)(part C)Time frame: From baseline to Week 26 and Week 52
  • RemovedHbA1c level at W26 and W52(part C)Time frame: at Week 26 and Week 52
  • RemovedHbA1c level change from baseline to W26 and W52(part C)Time frame: From baseline to Week 26 and Week 52
Nov 2, 2026
Title
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and ChildrenAdolescents on Top of Insulin Therapy (FABULINUS)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Eligibility Minimum age 6 Years→12 Years
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedChange in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from AUC from baseline to W26 for Part C (6-11 y.o.)Time frame: Baseline to Week 26
    Secondary outcomes 19 removed
    What changed in the outcomes
    • RemovedTime in range (70-180 mg/dL), assessed by study CGM at W26 and W52(part C)Time frame: At week 26 and week 52
    • RemovedTime in tight range (TITR, 70 - 140 mg/dL), assessed by study CGM at W26 and W52(part C)Time frame: At Week 26 and Week 52
    • RemovedChange from baseline to W52 in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from AUC(Part C)Time frame: From baseline to week 52
    • RemovedProportion of participants who remain C-peptide positive (mean 2h MMTT stimulated C-peptide concentration ≥0.2 nmol/L) at W26 and W52(part C)Time frame: At Week 26 and Week 52
    • RemovedProportion of participants with reduction from baseline to W26 and W52 of less than 10% in mean 2h MMTT stimulated C-peptide concentration(Part C)Time frame: From baseline to week 26 and week 52
    • RemovedProportion of participants with partial remission at W26 and W52 (defined as IDAA1c score ≤9.0, where it is calculated as HbA1c [%] + 4x insulin dose [IU/kg/day]) (part C)Time frame: At week 26 and week 52
    • RemovedChange from baseline to W26 and W52 in IDAA1c score(part C)Time frame: From baseline to Week 26 and Week 52
    • RemovedChange from baseline to W26 and W52 in insulin dose [IU/kg/day] (part C)Time frame: From baseline to Week 26 and Week 52
    • RemovedProportion of participants with HbA1c ≤6.5% and requiring no injections of exogenous insulin at W26 and W52(part C)Time frame: At week 26 and week 52
    • RemovedProportion of participants with HbA1c ≤6.5% and requiring ≤0.25 IU of insulin at W26 and W52(part C)Time frame: At week 26 and week 52
    • RemovedProportion of participants with HbA1c <7% at W26 and W52(part C)Time frame: At week 26 and week 52
    • RemovedChange from baseline to W26 and W52 in PedsQL Diabetes Symptoms domain score (all participants≥8 y.o.) (part C)Time frame: From baseline to Week 26 and Week 52
    • RemovedChange from baseline to W26 and W52 in [BB7.1][LS7.2]PedsQL Diabetes Management domain score (all participants≥8 y.o.) (part C)Time frame: From baseline to Week 26 and Week 52
    • RemovedChange from baseline to W26 and W52 in Problem Areas In Diabetes (PAID) total score (all participants)(part C)Time frame: From baseline to Week 26 and Week 52
    • RemovedChange in PedsQL Diabetes Symptoms and Management domains scores (caregivers of participants 6 -7 y.o.) from baseline to W26 and W52 (Part C)Time frame: From baseline to Week 26 and Week 52
    • RemovedChange from baseline to W26 and W52 in PAID immediate and theoretical domain scores (caregivers of all participants 6-17 y.o.)(part C)Time frame: From baseline to Week 26 and Week 52
    • RemovedChange from baseline to W26 and W52 [BB8.1]in DTSQs Total and item scores (caregivers of all participants 6-17 y.o.)(part C)Time frame: From baseline to Week 26 and Week 52
    • RemovedHbA1c level at W26 and W52(part C)Time frame: at Week 26 and Week 52
    • RemovedHbA1c level change from baseline to W26 and W52(part C)Time frame: From baseline to Week 26 and Week 52
    Title Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and ChildrenAdolescents on Top of Insulin Therapy (FABULINUS)
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06111586
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Dec 11, 2023
Primary completion
Apr 28, 2027 (estimated)
Completion
Oct 29, 2030 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Frexalimab

Start the discussion